Information on Offering costs incurred by the Company

Date: 19 May 2025

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

Subject: Information on Offering costs incurred by the Company
Further to Current Report No. 3/2025 of 6 February 2025, the Management Board of Diagnostyka S.A. (the “Company”) announces that the costs included in the costs of the public offering of 16,147,124 Company shares (the “Offering”) totalled PLN 3.41 million (the “Total Offering Costs”). The calculation includes costs incurred by the Company. In addition to these, a significant portion of the costs was paid by the shareholder selling shares in the IPO, i.e. LX Beta s.a.r.l.

Unless defined otherwise herein, all capitalised terms used in this Current Report have the meanings assigned to them in the Company’s Prospectus approved by the Financial Supervision Authority on 21 January 2025 (the “Prospectus”).

The Total Offering Costs included:

• costs of preparing and executing the Offering: PLN 2.20 million,
• underwriting fees – not applicable,
• cost of drafting the Prospectus, including advisory services: PLN 0.68 million,
• advertising costs: PLN 0.53 million.

Method applied to account for the Total Offering Costs in the Company’s accounting books: the Offering costs have been included in the costs of 2024 and 2025.

Method applied to disclose the Total Offering Costs in the Company’s financial statements: the costs have been charged against the net profit (loss) for 2024 and 2025.

Average Offering cost per Offer Share: PLN 0.21.

Legal basis:

Section 16.1.12 and 16.1.13 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state of 29 March 2018

For the Company:
Paweł Chytła – Vice President of the Management Board
Dariusz Zowczak – Vice President of the Management Board